Sanofi R&D Chief Elias Zerhouni On Partnerships, Drug Targets, And Market Dynamics
Executive Summary
As he steps down after a nine-year run as head of R&D, Zerhouni discusses the lessons he's learned and his major accomplishments.
You may also be interested in...
Sanofi Ready To Pull The Plug On Regeneron 'Life Support'
Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.